DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION EFFICACY TRIALS
VIRTUAL WORKSHOP SERIES
OCTOBER 2020 TO MAY 2021
#HIVPxTrialDesign
#HIVPxTrialDesign
HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic.
As a result, the design and conduct of the next generation of prevention trials is impacted and is further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.
The third session of the virtual workshop aims to reflect on novel scientific approaches for establishing efficacy of new biologics, community involvement and meaning full participation in trial design and regulatory approval. This session is supported by online presentations and three panel discussions.
Panel discussion on Novel Scientific Approaches for Establishing Efficacy of New Biologics
Chairs: Holly Janes and Deborah Donnell (Fred Hutchinson Cancer Research Center)
Panelists:
• Fei Gao, Fred Hutchinson Cancer Research Center
• Alex Luedtke, Department of Statistics, University of Washington
• Sheila Kansiime, LSHTM, Medical Research Council, Uganda Virus Research Institute,
• Dave Glidden, UCSF
• Peter Gilbert, Fred Hutchinson Cancer Research Center
The main goal of the panel discussion is to explore novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention and to identify gaps in knowledge or barriers to use of the statistical methods.
COMING SOON: 27 April 2021
Chair: Matthew Rose (HealthGap, Director US Policy and Advocacy)
Panelists:
• Nandi Luthuli (AVAC)
• Jim PIckett (AIDS Foundation Chicago)
• Rafael Gonzalez (HVTN)
• Kagisho Baepanye (HVTN)
• Dazon Dixon Diallo (SisterLove)
The main goal of this panel discussion is to address current trials across product modalities (e.g., vaccines, oral and injectable PrEP), community needs and considerations of current trials, then move into a broader discussion on community considerations of future trial designs, including acceptability, access, and meaningful engagement.
PrEPVacc trial statistical analysis plan
Sheila Kansiime, Ph.D.
LSHTM, Medical Research Council / Uganda Virus Research Institute, Uganda.
A brief overview of the PrEPvacc trial followed by a detailed presentation of the statistical analysis plan and some of its novel aspects.
A Bayesian Framework for Inferring Background HIV Incidence: An Application Using Tenofovir Drug Levels.
David Glidden, Ph.D.
University of California San Francisco, San Francisco, USA.
How to use Tenofovir pharmacology to help reconstruct an hypothetical placebo arm.
Estimation of Dapivirine vaginal ring efficacy in the HOPE trial
Alex Luedtke, Ph.D.
University of Washington, USA.
Evaluating vaccine efficacy of a candidate HIV vaccine vs. counterfactual placebo:
immune Mediator Approach
Peter Gilbert, Ph.D.
Fred Hutchinson Cancer Research Center, University of Washington, USA.
Design for active-arm trial with counterfactual placebo Incidence based on Recency test
Fei Gao, Ph.D.
Fred Hutchinson Cancer Research Center, University of Washington, USA.
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
IAS – the International AIDS Society
Avenue de France 23
CH-1202 Geneva
Switzerland
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy policy